Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share (SYRE)
CUSIP: 00773J202
Q3 2023 13F Holders as of 30 Sep 2023
- Type / Class
- Equity / Common Stock, $0.0001 Par Value Per Share
- Shares outstanding
- 86,389,920
- Total 13F shares
- 3,257,983
- Share change
- +3,257,983
- Total reported value
- $39,909,852
- Put/Call ratio
- 7.1%
- Price per share
- $12.25
- Number of holders
- 27
- Value change
- +$39,909,852
- Number of buys
- 27
Quarterly Holders Quick Answers
What is CUSIP 00773J202?
CUSIP 00773J202 identifies SYRE - Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Newer quarter: Q4 2023
Recent filing periods for CUSIP 00773J202:
Top shareholders of SYRE - Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Anthony G. Quinn |
3/4/5
|
President & CEO, Director |
—
class O/S missing
|
816,835
|
$579,952 | — | 16 Mar 2022 | |
| Marcio Souza |
3/4/5
|
Director |
—
class O/S missing
|
90,000
|
$63,900 | — | 25 Aug 2022 | |
| Jonathan Alspaugh |
3/4/5
|
President and CFO |
—
class O/S missing
|
19,787,969
|
— | — | 22 Jun 2023 | |
| Alison Frances Lawton |
3/4/5
|
Director |
—
class O/S missing
|
1,950,000
|
— | — | 22 Jun 2023 | |
| Hunter C. Smith |
3/4/5
|
Director |
—
class O/S missing
|
1,950,000
|
— | — | 22 Jun 2023 | |
| Ivana Magovcevic-Liebisch |
3/4/5
|
Director |
—
class O/S missing
|
1,950,000
|
— | — | 22 Jun 2023 | |
| Russell J. Cox |
3/4/5
|
Director |
—
class O/S missing
|
1,950,000
|
— | — | 22 Jun 2023 | |
| Jeff Marc Goldberg |
3/4/5
|
President and CEO, Director |
—
class O/S missing
|
1,884,838
|
— | — | 29 Nov 2022 | |
| Linda L. Neuman |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
550,000
|
— | — | 23 Feb 2023 | |
| James Paul Kastenmayer |
3/4/5
|
General Counsel |
—
class O/S missing
|
500,000
|
— | — | 23 Feb 2023 | |
| Jr. Michael Conick Hanley |
3/4/5
|
Chief Business Officer |
—
class O/S missing
|
500,000
|
— | — | 23 Feb 2023 | |
| Leslie Sloan |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
130,000
|
— | — | 23 Aug 2022 | |
| Armen Shanafelt |
3/4/5
|
Director |
—
class O/S missing
|
43,000
|
— | — | 07 Jun 2022 | |
| Bryan Lawlis V |
3/4/5
|
Director |
—
class O/S missing
|
43,000
|
— | — | 07 Jun 2022 | |
| Sandesh Mahatme |
3/4/5
|
Director |
—
class O/S missing
|
43,000
|
— | — | 07 Jun 2022 | |
| BAKER BROS. ADVISORS LP |
3/4/5
|
Director |
—
class O/S missing
|
40,000
|
— | — | 08 Jun 2021 | |
| Steven Weber |
3/4/5
|
VP, Controller&Princ Acctg Off |
—
class O/S missing
|
30,000
|
— | — | 17 Feb 2022 |
Institutional Holders of Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share (SYRE) as of Q3 2023
As of 30 Sep 2023,
Spyre Therapeutics, Inc. - Common Stock, $0.0001 Par Value Per Share (SYRE) was held by
27 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,257,983 shares.
The largest 10 holders included
Driehaus Capital Management LLC, Fairmount Funds Management LLC, Polar Capital Holdings Plc, WELLINGTON MANAGEMENT GROUP LLP, Affinity Asset Advisors, LLC, Logos Global Management LP, EcoR1 Capital, LLC, SUVRETTA CAPITAL MANAGEMENT, LLC, Rock Springs Capital Management LP, and COMMODORE CAPITAL LP.
This page lists
27
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q3 2023 vs Q4 2025 Across Filers
Q4 2025 holders
152
Q3 2023 holders
27
Holder diff
-125
| Investor | Q4 2025 Shares | Q3 2023 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q3 2023 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.